The expression of PD-L1 on the surface of tumor cells and immune cells, detected by immunohistochemistry, is the most used predictive biomarker used to guide treatment decisions with anti-PD-1 or anti-PD-L1 antibodies in patients with NSCLC. The gene discussed is CD274; the disease is neoplasm.